FLASH-THERAPEUTICS
5.2.2024 12:25:32 CET | Business Wire | Press release
Flash Therapeutics, a French CDMO specialized in the bioproduction of viral vectors for the transfer of genetic material, is extremely proud to count the CEA, in particular, l’Institut de biologie François Jacob - Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse – LGRK, among its major customers.
Thanks to the quality of Flash Therapeutics' vectors, the LGRK has been sourcing specific products from our company for over 10 years to support its research activities, in particular, to study the intrinsic properties and regenerative capacity of skin stem cells.
The CEA has published an excellent article on epidermal stem cells entitled " KLF4 inhibition promotes the expansion of keratinocyte precursors from adult human skin and of embryonic-stem-cell-derived keratinocytes " in Nature Biomed Engineering by Nicolas Fortunel & al.
Flash Therapeutics and the CEA's Institut de biologie François Jacob are currently discussing expanding their partnership, given their complementary nature.
Jérôme Bédier, CEO of Flash Therapeutics: "We are delighted to be partnering with the CEA, the leading French and European player in the field of energy and technology. This approach builds on more than 10 years of collaboration and is in line with Flash's key mission: to discover and bring forward innovative technologies for highly effective therapies on a commercial scale ".
About Flash Therapeutics: Founded in 2005 and based at the Oncopole site in Toulouse, Flash Therapeutics is a CDMO specialized in the industrial bioproduction of DNA and RNA vectors to cover a wide range of applications in gene and cell therapy and vaccines. Thanks to its robust platform and manufacturing process, Flash Therapeutics delivers high-purity, high-concentration viral vectors for research, pre-clinical, clinical and commercial phases.
About the CEA: The CEA's role is to inform public decision-making by providing scientific and technological solutions to the driving forces (companies, local authorities), to better manage major societal changes: energy transition, digital, healthcare of the future, global defence and security. Its 21,000 employees work at the heart of 9 centres equipped with major research infrastructures, as part of academic and industrial partnerships in France, Europe and internationally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205325698/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Linnea Achieves CEP Certification for Cannabidiol Isolate3.3.2026 08:25:00 CET | Press release
Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP). The CEP serves to attest that the quality of an active pharmaceutical ingredient (API) is adequately controlled by the monographs of the European Pharmacopoeia, ensuring its safety, quality and conformity for use in medicinal products in Europe. Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), the CEP represents an independent validation of consistency, safety, and regulatory compliance for the European market. This consequently simplifies the marketing authorization (MA) process for new medicines, as a detailed evaluation of the active substance by regulatory authorities is not required. This milestone represents a significant achievement for the company and reinforces its commitment to delivering consistent and high-quality cannabinoid ingredients. The certification provides customers and partners with as
Quectel Introduces FGH200M Wi-Fi HaLow Module for massive IoT Deployments3.3.2026 08:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FGH200M long range, low power Wi-Fi HaLow module. Based on the Morse Micro MM8108 chipset and operating in the sub-1GHz license exempt frequency band, the module delivers enhanced penetration and broader coverage, over a range of approximately 1km, while supporting low power consumption and large-scale device connectivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302200601/en/ Quectel introduces FGH200M Wi-Fi HaLow module for massive IoT deployments The FGH200M module adopts the IEEE 802.11ah wireless networking protocol, also known as Wi-Fi HaLow, operating in the license-exempt Sub-1GHz spectrum. Designed to meet the evolving requirements of IoT connectivity, the FGH200M delivers extended Sub-1GHz signal coverage, enabling reliable device control at distances of up to one kilometer. “We’re excited to unveil th
Quectel Expands Small Cell Antennas Portfolio With Five New Products3.3.2026 08:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, has introduced five new small cell antennas to add further functionality and provide greater flexibility and choice for customers designing and implementing small cell deployments. The new antennas bring an additional range of form factors, mounting options and performance characteristics to the Quectel antenna range. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302915004/en/ Quectel expands small cell antennas portfolio with five new products “Whether you’re looking for an antenna to support critical wireless communications, dense stadium usage scenarios or ultimate capacity, these five new Quectel antennas have been designed to meet your needs,” says David Wei, Antenna Product Head, Quectel Wireless Solutions. “The new antennas augment our already comprehensive range of antennas, bring further choice and add capabilities for developers and enginee
Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis3.3.2026 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodiesterase-4 (PDE4) inhibitor, has been granted orphan medicinal product designation by the European Commission (EC) for the treatment of palmoplantar pustulosis (PPP). Palmoplantar pustulosis is a chronic inflammatory disease characterized by the development of multiple sterile pustules on the palms and soles. Patients often experience pain and pruritus of the skin, and the condition can be accompanied by nail involvement and joint pain. Because lesions on the palms are visible to others and lesions on the soles can cause pain while walking, daily functioning can be significantly restricted, leading in a substantial reduction in quality of life. PPP has a pathophysiology distinct from psoriasis and pustular psoriasis, and treatment can be challenging, unde
IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses2.3.2026 22:15:00 CET | Press release
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its soy crush, concentrates and lecithin businesses to Bunge. This transaction does not include IFF’s soy isolates business. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260302231096/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom